CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators - The RAID Trial Dapagliflozin for treating chronic heart failure with reduced ejection fraction Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed

Guideline24 February 2021

JOURNAL:National Institue for Health and Care Excellence Article Link

Dapagliflozin for treating chronic heart failure with reduced ejection fraction

National Institue for Health and Care Excellence Keywords: HFrEF; guideline; NICE

Full Text PDF